Cancer Family
Pancreaticobiliary Neoplasm
CI-CAN-00000309Explore in graph →
Non-malignant1,205 active trials11 approved drugs92 evidence items
- NCIt
- C223357
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000309Explore in graph →
Clinical trials
5,005 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02403271 | A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 124 | Pharmacyclics LLC.INDUSTRY | 1 | Jan 3, 2019 | clinicaltrials |
| NCT01453153 | Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer | completed | Phase 1 / Phase 2 | 28 | Halozyme TherapeuticsINDUSTRY | 2 | Nov 30, 2018 | clinicaltrials |
| NCT03627390 | BP-C1 in Short-term Treatment of Metastatic Pancreatic Cancer | completed | Phase 2 | 16 | Meabco A/SINDUSTRY | 1 | Nov 15, 2018 | clinicaltrials |
| NCT00068432 | Gemcitabine and Celecoxib in Treating Patients With Metastatic Pancreatic Cancer | completed | Phase 2 | 28 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 31, 2018 | clinicaltrials |
| NCT00460174 | Gemcitabine, Bevacizumab, and Abdominal Radiation Therapy in Treating Patients With Localized Pancreatic Cancer | completed | Phase 2 | 31 | Northwestern UniversityOTHER | 1 | Oct 29, 2018 | clinicaltrials |
| NCT01032057 | Gemcitabine, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed by Surgery(SCALOP) | completed | Phase 2 | 114 | Lisette NixonOTHER | 1 | Oct 26, 2018 | clinicaltrials |
| NCT00003677 | Dolastatin 10 in Treating Patients With Metastatic Pancreatic Cancer | completed | Phase 2 | 9 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 25, 2018 | clinicaltrials |
| NCT02181634 | Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Cholangiocarcinoma(PrE0204) | completed | Phase 2 | 74 | PrECOG, LLC.OTHER | 2 | Oct 3, 2018 | clinicaltrials |
| NCT00557492 | Efficacy of Neoadjuvant Chemoradiation for Potentially Resectable Pancreas Cancer | completed | Phase 2 | 59 | Amer ZureikatOTHER | 1 | Sep 25, 2018 | clinicaltrials |
| NCT02399137 | A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer(CARRIE) | completed | Phase 2 | 88 | Merrimack PharmaceuticalsINDUSTRY | 6 | Sep 18, 2018 | clinicaltrials |
| NCT00019474 | Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer | completed | Phase 2 | 60 | Montefiore Medical CenterOTHER | 1 | Sep 14, 2018 | clinicaltrials |
| NCT00078975 | 3-AP and Gemcitabine in Treating Patients With Recurrent, Unresectable, or Metastatic Pancreatic Cancer | completed | Phase 2 | 26 | University Health Network, TorontoOTHER | 1 | Sep 14, 2018 | clinicaltrials |
| NCT00109941 | Opioid Growth Factor in Treating Patients With Advanced Pancreatic Cancer That Cannot Be Removed By Surgery(OGF) | completed | Phase 2 | 25 | Milton S. Hershey Medical CenterOTHER | 1 | Sep 6, 2018 | clinicaltrials |
| NCT01534637 | Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Chemotherapy and Radiation Therapy for Pancreatic Cancer | completed | Phase 2 | 22 | Wake Forest University Health SciencesOTHER | 1 | Aug 15, 2018 | clinicaltrials |
| NCT02558894 | Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma | completed | Phase 2 | 65 | AstraZenecaINDUSTRY | 6 | Aug 2, 2018 | clinicaltrials |
| NCT00408564 | Cetuximab, Gemcitabine, and Oxaliplatin Followed By Surgery or External-Beam Radiation Therapy and Capecitabine in Treating Patients With Locally Advanced, Nonmetastatic Pancreatic Cancer That Cannot Be Removed By Surgery | completed | Phase 2 | 39 | Medical University of South CarolinaOTHER | 1 | Jul 23, 2018 | clinicaltrials |
| NCT02558868 | Second-Line Oxaliplatin and Irinotecan Versus Irinotecan Alone for Gemcitabine and S-1 Refractory Pancreatic Cancer | completed | Phase 2 | 80 | Zhejiang UniversityOTHER | 1 | Jun 21, 2018 | clinicaltrials |
| NCT02609958 | ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy | completed | Phase 2 | 32 | ASLAN PharmaceuticalsOTHER | 3 | May 29, 2018 | clinicaltrials |
| NCT01389440 | Efficacy and Safety of a Neoadjuvant Treatment in Pancreatic Cancer(GEMCAD1003) | completed | Phase 2 | 24 | Grupo Espanol Multidisciplinario del Cancer DigestivoOTHER | 1 | May 18, 2018 | clinicaltrials |
| NCT01373164 | A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer | completed | Phase 1 / Phase 2 | 170 | Eli Lilly and CompanyINDUSTRY | 6 | May 16, 2018 | clinicaltrials |
| NCT01912053 | Efficacy Study of Intra-hepatic Administration of Therasphere® in Association With Intravenous Chemotherapy to Treat Cholangiocarcinoma(MispheC) | completed | Phase 2 | 41 | Center Eugene MarquisOTHER | 1 | May 11, 2018 | clinicaltrials |
| NCT01417000 | Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic Cancer | completed | Phase 2 | 93 | Aduro Biotech, Inc.INDUSTRY | 1 | May 8, 2018 | clinicaltrials |
| NCT01458717 | Neoadjuvant Chemoradiation in Patients With Borderline Resectable Pancreatic Cancer | completed | Phase 2 / Phase 3 | 58 | Seoul National University HospitalOTHER | 1 | May 2, 2018 | clinicaltrials |
| NCT00142480 | Capecitabine, Oxaliplatin, Bevacizumab and Radiation Therapy in Patients With Biliary Tract and Gallbladder Cancer | completed | Phase 2 | 8 | Massachusetts General HospitalOTHER | 1 | Apr 25, 2018 | clinicaltrials |
| NCT02284139 | Pilot Trial of EGF Ointment for the Patients With EGFR-i Related Skin Side Effects | completed | Phase 2 / Phase 3 | 90 | Dong-A University HospitalOTHER | 1 | Apr 23, 2018 | clinicaltrials |
| NCT00101036 | Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery | completed | Phase 2 | 57 | National Cancer Institute (NCI)NIH | 1 | Apr 20, 2018 | clinicaltrials |
| NCT00839332 | A Study for Participants With Pancreatic Cancer | completed | Phase 1 / Phase 2 | 157 | Eli Lilly and CompanyINDUSTRY | 6 | Apr 17, 2018 | clinicaltrials |
| NCT00789958 | S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct | completed | Phase 2 | 105 | SWOG Cancer Research NetworkNETWORK | 1 | Apr 9, 2018 | clinicaltrials |
| NCT01888978 | Molecularly Tailored Therapy for Pancreas Cancer | completed | Phase 2 | 19 | Georgetown UniversityOTHER | 1 | Apr 9, 2018 | clinicaltrials |
| NCT01280058 | Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer | completed | Phase 2 | 73 | National Cancer Institute (NCI)NIH | 1 | Mar 9, 2018 | clinicaltrials |
| NCT01024387 | AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors | completed | Phase 2 | 60 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 8, 2018 | clinicaltrials |
| NCT01423604 | Study of Ruxolitinib in Pancreatic Cancer Patients(RECAP) | completed | Phase 2 | 136 | Incyte CorporationINDUSTRY | 1 | Feb 12, 2018 | clinicaltrials |
| NCT01963325 | S-1 in Combination With Abraxane in Treating Cholangiocarcinoma | completed | Phase 2 | 50 | Yuhong LiOTHER | 1 | Feb 5, 2018 | clinicaltrials |
| NCT02806648 | A Trial to Assess the Activity and Safety of Palbociclib in Patients With Well and Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET)(PALBONET) | completed | Phase 2 | 21 | Grupo Espanol de Tumores NeuroendocrinosOTHER | 1 | Jan 23, 2018 | clinicaltrials |
| NCT00365144 | Bevacizumab and Erlotinib in Treating Patients With Metastatic Pancreatic Cancer That Did Not Respond to Previous Treatment With Gemcitabine | completed | Phase 2 | 36 | University of California, San FranciscoOTHER | 1 | Jan 19, 2018 | clinicaltrials |
| NCT01781520 | Study of S-1 Plus DC-CIK for Patients With Unresectable Locally Advanced Pancreatic Cancer | completed | Phase 1 / Phase 2 | 47 | Capital Medical UniversityOTHER | 1 | Jan 18, 2018 | clinicaltrials |
| NCT00810719 | Gemcitabine and Erlotinib in Treating Patients With Metastatic or Recurrent Pancreatic Cancer | completed | Phase 2 | 30 | University of California, DavisOTHER | 1 | Jan 10, 2018 | clinicaltrials |
| NCT01234935 | Dasatinib and Gemcitabine Hydrochloride or Gemcitabine Hydrochloride Alone in Treating Patients With Pancreatic Cancer Previously Treated With Surgery | completed | Phase 2 | 8 | Translational Oncology Research InternationalOTHER | 1 | Jan 9, 2018 | clinicaltrials |
| NCT01043172 | A Study of Gemcitabine as an Adjuvant Treatment for Cholangiocarcinoma After Surgical Resection | completed | Phase 2 | 72 | National Cancer Center, KoreaOTHER_GOV | 1 | Jan 3, 2018 | clinicaltrials |
| NCT01146054 | Phase II Gemcitabine + Fractionated Stereotactic Radiotherapy for Unresectable Pancreatic Adenocarcinoma | completed | Phase 2 | 59 | Stanford UniversityOTHER | 1 | Dec 19, 2017 | clinicaltrials |
| NCT00290693 | Capecitabine and Docetaxel in Treating Patients With Recurrent or Progressive Metastatic Pancreatic Cancer | completed | Phase 2 | 45 | University of MiamiOTHER | 1 | Dec 2, 2017 | clinicaltrials |
| NCT00201838 | Etanercept and Gemcitabine in Patients With Advanced, Chemotherapy Naive Pancreatic Adenocarcinoma | completed | Phase 1 / Phase 2 | 38 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Nov 30, 2017 | clinicaltrials |
| NCT01430052 | Chemoradiotherapy With Gemcitabine/S-1 vs Gemcitabine/S-1 for Locally Advanced Pancreatic Cancer | completed | Phase 2 | 110 | Osaka Medical Center for Cancer and Cardiovascular DiseasesOTHER | 1 | Nov 21, 2017 | clinicaltrials |
| NCT00383760 | Eribulin Mesylate as Second-Line Therapy for Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer Patients | completed | Phase 2 | 15 | National Cancer Institute (NCI)NIH | 1 | Oct 20, 2017 | clinicaltrials |
| NCT01320254 | PiCCA Study (Panitumumab in Combination With Cisplatin/Gemcitabine)(PiCCA) | completed | Phase 2 | 93 | Hannover Medical SchoolOTHER | 1 | Oct 12, 2017 | clinicaltrials |
| NCT02017015 | Safety and Efficacy Study of Nab-paclitaxel Plus Gemcitabine in Chinese Patients With Metastatic Pancreatic Cancer(PANC-001) | completed | Phase 2 | 83 | CelgeneINDUSTRY | 1 | Sep 26, 2017 | clinicaltrials |
| NCT00033540 | S0202 Gemcitabine and Capecitabine for Unresectable Locally Advanced Metastatic Gallbladder Cancer or Cholangiocarcinoma | completed | Phase 2 | 57 | SWOG Cancer Research NetworkNETWORK | 1 | Sep 12, 2017 | clinicaltrials |
| NCT02042443 | Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery(S1310) | completed | Phase 2 | 53 | National Cancer Institute (NCI)NIH | 1 | Sep 12, 2017 | clinicaltrials |
| NCT01553019 | Postoperative Proton Radiotherapy With Chemo for Pancreatic Cancer(PC03) | completed | Phase 2 | 2 | University of FloridaOTHER | 1 | Sep 6, 2017 | clinicaltrials |
| NCT01150630 | Gemcitabine, Cisplatin, Epirubicin, and Capecitabine in Treating Patients With Stage I-II Resectable Pancreatic Cancer(PACT-15) | completed | Phase 2 | 98 | IRCCS San RaffaeleOTHER | 1 | Sep 1, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Jan 3, 2019source: clinicaltrials